Ionis Pharmaceuticals
IONS
513 hedge funds and large institutions have $14.3B invested in Ionis Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 67 funds opening new positions, 200 increasing their positions, 160 reducing their positions, and 46 closing their positions.
58% more call options, than puts
Call options by funds: $395M | Put options by funds: $250M
46% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 46
25% more repeat investments, than reductions
Existing positions increased: 200 | Existing positions reduced: 160
10% more capital invested
Capital invested by funds: $13B → $14.3B (+$1.3B)
4.26% more ownership
Funds ownership: 104.49% → 108.74% (+4.3%)
3% more funds holding
Funds holding: 496 → 513 (+17)
36% less funds holding in top 10
Funds holding in top 10: 14 → 9 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$179M |
| 2 |
Barclays
London,
United Kingdom
|
+$98.8M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$94.8M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$71.1M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$166M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$63.7M |
| 3 |
Millennium Management
New York
|
-$57.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$53.1M |
| 5 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
-$46.4M |
IONS Hedge Fund Activity: Q2 2026 in Review
513 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q2 2026, worth a combined $14.3B — up 10% from $13B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new IONS positions and 46 closed out — a net gain of 21 holders — while 200 added to existing stakes and 160 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $179M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $166M.
- 513 institutional investors held Ionis Pharmaceuticals (IONS) as of Q2 2026, up from 496 in Q1 2026.
- Funds reported $14.3B of Ionis Pharmaceuticals stock for Q2 2026, up 10% quarter-over-quarter.
- 67 funds opened new Ionis Pharmaceuticals positions in Q2 2026 and 46 closed out, a net change of +21 holders.
- The largest Ionis Pharmaceuticals buyer in Q2 2026 was Royal Bank of Canada, an estimated $179M added.
- The largest Ionis Pharmaceuticals seller in Q2 2026 was T. Rowe Price Investment Management, an estimated $166M sold.
Based on aggregated 13F filings for Q2 2026.